On February 5, 2026, OpenAI introduced GPT-5.3-Codex and wrote in its release notes that early versions of the model were “instrumental in creating itself,” helping to debug training runs, manage ...

The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...

Anthropic announced it's expanding its Claude Startups program, which gives members access to thousands of dollars' worth of Anthropic's Claude products and credits. The expansion marks the AI company ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The rise of generative AI and agentic AI, with AI coding tools capabilities, has created a ...

Researchers looked back at the baby-boom era and found that federal mortgage programs played a part in the country’s population upswing after World War II. By Sabrina Tavernise Puzzling over the ...

Stack BTC has agreed to buy gold dealer Direct Bullion for up to £12 million in a reverse takeover on the Aquis exchange. The deal is the firm’s first acquisition under a strategy of using operating ...

This score calculates overall vulnerability severity from 0 to 10 and is based on the Common Vulnerability Scoring System (CVSS). Attack vector: More severe the more the remote (logically and ...

Despite the hype, an AI-based miracle cure has yet to arise. But a different medical breakthrough may be on the horizon, courtesy of an AI-designed drug that early trials suggest could reverse the ...

The Minister of Urban and Rural Development, James Sankwasa, has ordered local authorities in the ||Kharas and Hardap regions to reverse their decisions to write off pensioners’ debts. He said the ...

Emerald AI, now valued at $1.05 billion, uses software to keep power demand at the computing facilities from getting out of control. By Sri Muppidi Silicon Valley Power is nowhere near the size of the ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...